CPHI & PMEC India 2022 announced at Pre Connect Congress

Theme of the event was #GetPharmore

Organized by Informa Markets in association with Fette Compacting and Wellonia.be

The 15th edition of CPHI & PMEC India 2022 – a premier pharma industry exhibition — was announced on 28 November at the Pre Connect Congress in Crowne Plaza Hotel, Mayur Vihar, New Delhi. Organized by Informa Markets in association with Fette Compacting and Wellonia with the theme #GetPharmore, the pre-event witnessed a large gathering of industry experts, leading manufacturers, buyers, policy advisers and regulators, and many key stakeholders.

CPHI & PMEC India 2022 is being held from 29 November to December 1 at India Expo Mart, Greater Noida.

Digital transformation for the supply chain and the adoption of new technology will play a key role in the growth of the pharma industry. It has been observed by many experts that most of the innovations that are available in the market are not put to use by industrialists due to lack of information on the subject. This results in the decline of the machinery market, which has been a hindrance in the growth of the pharma sector for a long time.

“Knowing the problem is one thing but a complete understanding of the problem should be our first priority,” said Martin Scholer from Fette Compacting. “Perception plays a vital role; you cannot solve a problem while thinking of the problem instead of the solution.”

Rajiv Singh Raghuvanshi from Wellonia said, “The generic medicine industry is incapable of leading India to the global pharma platform. Any amount of innovations, government policies, and incentives will not work in favor of this. Enhancement in the complex generics and research on molecules and biologics will make things go better. The companies providing good enough ecosystems that nurture innovations will always have the upper hand.”

A delay in the approval for medicines hampers market reach and the overall growth of the pharma industry, said Shubhdeep Sinha of Wellonia. “Success rate of biosimilars is alluding and the lack of regulations makes matters worse for the research and production segments. Complete revamping of the regulations will be able to encourage growth. Excellence is measured by project completion so a visible work culture among industries will not just encourage risk-taking but will also provide tangible results.”


Please enter your comment!
Please enter your name here